Major AI, Robotics and Biotech Funding Rounds and Market Signals August 2026
In August 2026 a series of large capital raises, insider purchases and industry forecasts highlighted growing investment in AI infrastructure, general‑purpose robotics and AI‑enabled biotech.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Alibaba priced a placement of 710 million new shares at HK$112.70 each, raising roughly HK$80 billion, with the net proceeds earmarked for full‑stack AI capabilities and infrastructure. Shortly after, Jack Ma bought more than HK$600 million of the company’s Hong Kong‑listed shares, while co‑founder Joe Tsai and CEO Eddie Wu purchased about HK$202 million combined, signalling senior confidence despite the 8.4% discount to the prior close and the dilution impact [3].
Semiconductor analyst Dylan Patel projected that OpenAI and Anthropic will dominate the majority of usable global AI compute by the end of 2028. He noted each lab controlled about 2 GW of compute at the start of 2026 and expects that to rise to 5 GW by year‑end, giving them 40‑50% of incremental compute next year and 70‑80% by 2028, driven by highly profitable inference operations that fund further model training [4].
AM Intelligence (AMI) announced an order for 9,000 Nvidia Vera Rubin chips as it builds a 5 GW global AI data‑centre network, planning to deploy 200 MW of capacity over the next 18 months. The expansion is backed by $3 billion of combined debt and equity financing, aimed at serving global AI customers and model‑training workloads [5].
Robotics
Robotics startup Generalist raised an additional nearly $200 million in an extension of its Series B round, bringing total Series B funding to $600 million and lifting its post‑money valuation to $3 billion. The round was led by 8VC and followed a June $400 million raise led by Radical Ventures at a $2 billion valuation. Founded by former Google DeepMind researchers Pete Florence and Andy Zeng and ex‑Boston Dynamics engineer Andrew Barry, Generalist is developing a Gen 1.5 foundation model that teaches robots new tasks from video clips as short as three to twelve seconds [2][1].
XPeng’s robotics unit, Dogotix, secured more than $900 million in a financing round that valued the business at over $6.3 billion post‑money, with a pre‑money valuation of $5 billion. The round was led by IDG Capital, included Gaorong Ventures, and counted Tencent and Alibaba as strategic investors. Proceeds will fund hardware and software R&D for the IRON humanoid robot, data collection, Physical AI model training, mass‑production facilities and international expansion, targeting a production rate of 1,000 units per month by the end of 2026 and commercial deliveries in 2027 [6][7].
Genetic Engineering
Airway Therapeutics closed a $50 million equity round comprising $26 million from a prior SAFE and $24 million from a Series E‑2 financing, with roughly 94% of existing investors participating, including Cincinnati Children’s and a syndicate of large family offices. The capital will primarily support the Phase 2b/3 trial of zelpultide alfa for preventing bronchopulmonary dysplasia in very preterm infants, as well as associated CMC and analytical activities required for late‑stage development [8].